{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:46:03Z","timestamp":1781077563873,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To determine if late phase is superior to arterial phase intraindividually regarding conspicuity of MPM in contrast enhanced chest MDCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>28 patients with MPM were included in this retrospective study. For all patients, chest CT in standard arterial phase (scan delay ca. 35\u2009s) and abdominal CT in portal venous phase (scan delay ca. 70\u2009s) was performed. First, subjective analysis of tumor conspicuity was done independently by two radiologists. Second, objective analysis was done by measuring Hounsfield units (HU) in tumor lesions and in the surrounding tissue in identical locations in both phases. Differences of absolute HUs in tumor lesions between phases and differences of contrast (HU in lesion \u2013 HU in surrounding tissue) between phases were determined. HU measurements were compared using paired t-test for related samples. Potential confounding effects by different technical and epidemiological parameters between phases were evaluated performing a multiple regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Subjective analysis: In all 28 patients and for both readers conspicuity of MPM was better on late phase compared to arterial phase. Objective analysis: MPM showed a significantly higher absolute HU in late phase (75.4 vs 56.7 HU,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.001). Contrast to surrounding tissue was also significantly higher in late phase (difference of contrast between phases 18.5 HU, SD 10.6 HU,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.001). Multiple regression analysis revealed contrast phase and tube voltage to be the only significant independent predictors for tumor contrast.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In contrast enhanced chest-MDCT for MPM late phase scanning seems to provide better conspicuity and higher contrast to surrounding tissue compared to standard arterial phase scans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08842-0","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T08:02:54Z","timestamp":1635235374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Conspicuity of malignant pleural mesothelioma in contrast enhanced MDCT \u2013 arterial phase or late phase?"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9716-011X","authenticated-orcid":false,"given":"Lukas","family":"Luerken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp Laurin","family":"Thurn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Zeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stroszczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okka Wilkea","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"8842_CR1","doi-asserted-by":"publisher","unstructured":"Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer:666\u201372. https:\/\/doi.org\/10.1038\/sj.bjc.6690105 .","DOI":"10.1038\/sj.bjc.6690105"},{"key":"8842_CR2","doi-asserted-by":"publisher","unstructured":"Neumann V, L\u00f6seke S, Nowak D, Herth FJF, Tannapfel A. Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. Dtsch Arztebl Int:319\u201326. https:\/\/doi.org\/10.3238\/arztebl.2013.0319 .","DOI":"10.3238\/arztebl.2013.0319"},{"key":"8842_CR3","doi-asserted-by":"publisher","unstructured":"Rusch VW. A Proposed New International TNM Staging System for Malignant Pleural Mesothelioma. Chest:1122\u20138. https:\/\/doi.org\/10.1378\/chest.108.4.1122 .","DOI":"10.1378\/chest.108.4.1122"},{"key":"8842_CR4","doi-asserted-by":"publisher","unstructured":"Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol:1631\u20139. https:\/\/doi.org\/10.1097\/JTO.0b013e31826915f1 .","DOI":"10.1097\/JTO.0b013e31826915f1"},{"key":"8842_CR5","doi-asserted-by":"publisher","unstructured":"Nickell LT, Lichtenberger JP, Khorashadi L, Abbott GF, Carter BW. Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. Radiographics a review publication of the Radiological Society of North America, Inc. p. 1692\u2013706. https:\/\/doi.org\/10.1148\/rg.346130089 .","DOI":"10.1148\/rg.346130089"},{"issue":"6","key":"8842_CR6","doi-asserted-by":"publisher","first-page":"1900953","DOI":"10.1183\/13993003.00953-2019","volume":"55","author":"A Scherpereel","year":"2020","unstructured":"Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953. https:\/\/doi.org\/10.1183\/13993003.00953-2019.","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"8842_CR7","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","volume":"73","author":"I Woolhouse","year":"2018","unstructured":"Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73(Suppl 1):i1\u2013i30. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-211321.","journal-title":"Thorax"},{"key":"8842_CR8","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Malignant Pleural Mesothelioma. Version2","author":"National Comprehensive Cancer Network","year":"2021","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Malignant Pleural Mesothelioma. Version2.2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpm.pdf Published 2021. Accessed 29 April 2021."},{"issue":"13","key":"8842_CR9","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(13):1343\u201373. https:\/\/doi.org\/10.1200\/JCO.2017.76.6394.","journal-title":"J Clin Oncol"},{"key":"8842_CR10","doi-asserted-by":"publisher","unstructured":"van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis:E254\u2013307. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2013.11.28 .","DOI":"10.3978\/j.issn.2072-1439.2013.11.28"},{"key":"8842_CR11","doi-asserted-by":"publisher","unstructured":"Benamore RE, O'Doherty MJ, Entwisle JJ. Use of imaging in the management of malignant pleural mesothelioma. Clin Radiol:1237\u201347. https:\/\/doi.org\/10.1016\/j.crad.2005.05.015 .","DOI":"10.1016\/j.crad.2005.05.015"},{"key":"8842_CR12","doi-asserted-by":"publisher","unstructured":"Raj V, Kirke R, Bankart MJ, Entwisle JJ. Multidetector CT imaging of pleura: comparison of two contrast infusion protocols. Br J Radiol:796\u20139. https:\/\/doi.org\/10.1259\/bjr\/55980445 .","DOI":"10.1259\/bjr\/55980445"},{"key":"8842_CR13","doi-asserted-by":"publisher","unstructured":"Tsim S, Stobo DB, Alexander L, Kelly C, Blyth KG. The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. Lung Cancer (Amsterdam, Netherlands):38\u201343. https:\/\/doi.org\/10.1016\/j.lungcan.2016.11.010 .","DOI":"10.1016\/j.lungcan.2016.11.010"},{"issue":"Suppl 2","key":"8842_CR14","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thx.2007.087619","volume":"62 Suppl 2","author":"British Thoracic Society Standards of Care Committee","year":"2007","unstructured":"British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax. 2007;62 Suppl 2(Suppl 2):ii1\u2013ii19. https:\/\/doi.org\/10.1136\/thx.2007.087619.","journal-title":"Thorax"},{"key":"8842_CR15","unstructured":"Deutsche Roentgengesellschaft. Stellungnahmen und Empfehlungen | AG Thoraxdiagnostik. https:\/\/www.ag-thorax.drg.de\/de-DE\/376\/stellungnahmen-und-empfehlungen\/ Published 2008. Accessed 29 April 2021."},{"key":"8842_CR16","doi-asserted-by":"publisher","unstructured":"Arenas-Jimenez JJ, et al. Early and delayed phases of contrast-enhanced CT for evaluating patients with malignant pleural effusion. Results of pairwise comparison by multiple observers. Br J Radiol. 2018:91. https:\/\/doi.org\/10.1259\/bjr.20180254 .","DOI":"10.1259\/bjr.20180254"},{"key":"8842_CR17","doi-asserted-by":"publisher","unstructured":"Nowak AK, Chansky K, Rice DC, et al. The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol:2089\u201399. https:\/\/doi.org\/10.1016\/j.jtho.2016.08.147 .","DOI":"10.1016\/j.jtho.2016.08.147"},{"key":"8842_CR18","doi-asserted-by":"publisher","unstructured":"Patel AM, Berger I, Wileyto EP, et al. The value of delayed phase enhanced imaging in malignant pleural mesothelioma. J Thorac Dis:2344\u20139. https:\/\/doi.org\/10.21037\/jtd.2017.07.86 .","DOI":"10.21037\/jtd.2017.07.86"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08842-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08842-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08842-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T03:05:34Z","timestamp":1645585534000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08842-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8842"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08842-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-554728\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"17 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Open Access funding statement has been added.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the institutional review board and the independent ethics committee at the University of Regensburg. Written informed consent from patients for the use and publication of their data in any form was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1144"}}